World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
114
Citations
77035
World Ranking
4622
National Ranking
129

Overview

Peter Hersey is affiliated with the University of Sydney in Australia and has contributed extensively to research in medicine, particularly within the fields of biochemistry, genetics, and molecular biology. Their academic focus spans molecular biology, oncology, immunology, epidemiology, and cancer research.

The scientist's work has covered several main topics, including:

  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Melanoma and MAPK Pathways
  • Immunotherapy and Immune Responses
  • Cutaneous Melanoma Detection and Management
  • Histone Deacetylase Inhibitors Research
  • Protein Degradation and Inhibitors

Peter Hersey has published a number of papers in well-known journals. Recent publications include:

  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy, 2020, Annals of Oncology
  • Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma, 2020, European Journal of Cancer
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma, 2020, Journal of Investigative Dermatology

Frequent co-authors who have collaborated with Peter Hersey include:

  • Jessamy Tiffen
  • Abdullah Al Emran
  • Stuart Gallagher
  • Hsin-Yi Tseng
  • Tom Sams

Publishing consistently, the scientist has contributed multiple times to several journals, most notably:

  • European Journal of Cancer
  • Journal of Investigative Dermatology
  • Cancers
  • The Lancet Oncology
  • Annals of Oncology

Best Publications

  • The Immune Landscape of Cancer

    Vésteinn Thorsson;David L Gibbs;Scott D Brown;Denise Wolf

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • Oncogenic Signaling Pathways in The Cancer Genome Atlas

    Francisco Sanchez-Vega;Marco Mina;Joshua Armenia;Walid K. Chatila

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Genomic Classification of Cutaneous Melanoma

    Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert

  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

    Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan

  • Comprehensive Characterization of Cancer Driver Genes and Mutations.

    Matthew H Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

  • Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

    K T Flaherty;C Robert;P Hersey;P Nathan;P Nathan

  • Whole-genome landscapes of major melanoma subtypes

    Nicholas K. Hayward;Nicholas K. Hayward;James S. Wilmott;Nicola Waddell;Nicola Waddell;Peter A. Johansson

  • Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

    Mark B. Faries;John F. Thompson;Alistair J. Cochran;Robert H. Andtbacka

  • Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi

  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy

    Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

    O. Hamid;C. Robert;C. Robert;A. Daud;F.S. Hodi

  • Pathogenic Germline Variants in 10,389 Adult Cancers

    Kuan-Lin Huang;R Jay Mashl;Yige Wu;Deborah I Ritter

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

  • Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group

    Agop Y. Bedikian;Michael Millward;Hubert Pehamberger;Robert Conry

  • Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

    F. Stephen Hodi;Wen Jen Hwu;Richard Kefford;Jeffrey S. Weber

Frequent Co-Authors

Richard F. Kefford
Richard F. Kefford Macquarie University
Richard A. Scolyer
Richard A. Scolyer Royal Prince Alfred Hospital
Caroline Robert
Caroline Robert University of Paris-Saclay
Georgina V. Long
Georgina V. Long University of Sydney
John F. Thompson
John F. Thompson University of Sydney
James S. Wilmott
James S. Wilmott University of Sydney
Antoni Ribas
Antoni Ribas University of California, Los Angeles
William H. McCarthy
William H. McCarthy University of Sydney
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Adil Daud
Adil Daud University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn’t always mean becoming a doctor. There are a variety of in-demand online degrees that can lead to rewarding roles within healthcare. Many programs offer flexibility for working professionals, making it easier to balance school, work, and personal commitments.

Students interested in healthcare leadership might consider affordable online mha programs, which teach skills for managing hospitals, clinics, and healthcare systems. Those aiming for advanced clinical practice may look at dnp online programs cheap to pursue roles such as nurse practitioner or clinical nurse leader.

The demand for pharmacy professionals is rising, and pharm d online programs allow you to specialize in medication management and patient care. Additionally, students interested in the growing field of healthcare technology can explore him programs to manage patient data and ensure information security.

Exploring these pathways can help you find the right fit for your career goals—with the convenience and affordability of online learning.

Best Scientists Citing Peter Hersey

Trending Scientists

Recently Published Articles